Heo Mi Jeong, Kim Young Mi, Koo Ja Hyun, Yang Yoon Mee, An Jihyun, Lee Sook-Kyung, Lee Seung Jin, Kim Kang Mo, Park Joong-Won, Kim Sang Geon
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea;
Oncotarget. 2014 May 15;5(9):2792-806. doi: 10.18632/oncotarget.1920.
Hepatocellular carcinoma (HCC) is classified as a poor prognostic tumor, and becomes frequently aggressive. MicroRNAs emerge as key contributors to tumor progression. This study investigated whether miR-148a dysregulation differentiates poor prognosis of HCC, exploring new targets of miR-148a. miR-148a dysregulation discriminated not only the overall survival and recurrence free survival rates of HCC, but the microvascular invasion. In the human HCC samples, ubiquitin specific protease 4 (USP4) and sphingosine 1-phosphate receptor 1 (S1P1) were up-regulated as the new targets of miR-148a. USP4 and S1P1 were up-regulated in mesenchymal-type liver-tumor cells with miR-148a dysregulation, facilitating migration and proliferation of tumor cells. The inverse relationship between miR-148a and the identified targets was verified in a tumor xenograft model. In the analysis of human samples, the expression of USP4, but not S1P1, correlated with the decrease of miR-148a. In a heterotropic patient-derived HCC xenograft model, USP4 was also overexpressed in G1 and G2 tumors when miR-148a was dysregulated, reflecting the closer link between miR-148a and USP4 for a shift in the expansion phase of tumorgraft. In conclusion, miR-148a dysregulation affects the poor prognosis of HCC. Of the identified targets of miR-148a, USP4 overexpression may contribute to HCC progression towards more aggressive feature.
肝细胞癌(HCC)被归类为预后不良的肿瘤,且常常具有侵袭性。微小RNA成为肿瘤进展的关键因素。本研究调查了miR-148a失调是否可区分HCC的不良预后,并探索miR-148a的新靶点。miR-148a失调不仅可区分HCC的总生存率和无复发生存率,还可区分微血管侵犯情况。在人类HCC样本中,泛素特异性蛋白酶4(USP4)和1-磷酸鞘氨醇受体1(S1P1)作为miR-148a的新靶点被上调。在miR-148a失调的间充质型肝肿瘤细胞中,USP4和S1P1上调,促进肿瘤细胞的迁移和增殖。在肿瘤异种移植模型中验证了miR-148a与已鉴定靶点之间的负相关关系。在对人类样本的分析中,USP4的表达与miR-148a的降低相关,而S1P1则不然。在异种移植的患者源性HCC模型中,当miR-148a失调时,USP4在G1和G2肿瘤中也过表达,这反映了miR-148a与USP4之间在肿瘤移植扩展阶段的转变上存在更紧密的联系。总之,miR-148a失调影响HCC的不良预后。在已鉴定的miR-148a靶点中,USP4的过表达可能导致HCC向更具侵袭性的特征发展。